Benjamin F. Chong
YOU?
Author Swipe
View article: Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors
Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors Open
Chimeric Antigen Receptor (CAR) T cells have induced remarkable clinical responses in patients with hematological cancers. However, CAR T-cell therapies against solid tumors have not elicited similar outcomes since immunosuppressive barrie…
View article: A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus Open
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progressio…
View article: Association of truncal involvement in lupus erythematosus panniculitis patients with calcinosis cutis: A retrospective cohort study
Association of truncal involvement in lupus erythematosus panniculitis patients with calcinosis cutis: A retrospective cohort study Open
Background Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus that typically presents as indurated nodules or plaques. Calcinosis cutis (CC) is a potential complication of this disease with limited tr…
View article: CD38 IS OVEREXPRESSED BY IMMUNE CELLS IN CUTANEOUS LUPUS SKIN
CD38 IS OVEREXPRESSED BY IMMUNE CELLS IN CUTANEOUS LUPUS SKIN Open
O019 / #487 Topic: AS07 - Cutaneous Lupus ABSTRACT CONCURRENT SESSION 03: INNATE AND ADAPTIVE IMMUNITY IN SLE 22-05-2025 1:40 PM - 2:40 PM Background/Purpose Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease in which metabo…
View article: STUDY OF ANTI-MALARIALS IN INCOMPLETE LUPUS – THE SMILE TRIAL
STUDY OF ANTI-MALARIALS IN INCOMPLETE LUPUS – THE SMILE TRIAL Open
O056 / #121 Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes ABSTRACT CONCURRENT SESSION 09: SLE THERAPY – REVISITING OLD DRUGS AND UNLOCKING HIDDEN POTENTIAL OF NEW MEDICATIONS 24-05-2025 10:40 AM - 11:40 AM Background/Purpose Pati…
View article: FRAMEWORK FOR IMPLEMENTING TREAT-TO-TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS ROUTINE CLINICAL CARE: CONSENSUS STATEMENTS FROM AN INTERNATIONAL TASK FORCE.
FRAMEWORK FOR IMPLEMENTING TREAT-TO-TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS ROUTINE CLINICAL CARE: CONSENSUS STATEMENTS FROM AN INTERNATIONAL TASK FORCE. Open
O034 / #681 Topic: AS09 - Emerging Approaches in SLE Management ABSTRACT CONCURRENT SESSION 05: EMERGING INSIGHTS ON THE MANAGEMENT OF LUPUS MANIFESTATIONS AND COMORBIDITIES 23-05-2025 1:40 PM - 2:40 PM Background/Purpose The adoption of T…
View article: CALCINOSIS CUTIS IN LUPUS ERYTHEMATOSUS PANNICULITIS SHOW PREDILECTION FOR TRUNCAL LOCATION
CALCINOSIS CUTIS IN LUPUS ERYTHEMATOSUS PANNICULITIS SHOW PREDILECTION FOR TRUNCAL LOCATION Open
PV061 / #136 Poster Topic: AS07 - Cutaneous Lupus Background/Purpose Lupus erythematosus panniculitis (LEP) is a rare form of chronic cutaneous lupus erythematosus characterized by indurated nodules or plaques resulting in pronounced skin …
View article: ERYTHEMA AND SCALE INFLUENCE QUALITY OF LIFE AND IMPRESSION OF DISEASE PROGRESSION IN CUTANEOUS LUPUS PATIENTS
ERYTHEMA AND SCALE INFLUENCE QUALITY OF LIFE AND IMPRESSION OF DISEASE PROGRESSION IN CUTANEOUS LUPUS PATIENTS Open
O017 / #393 Topic: AS07 - Cutaneous Lupus ABSTRACT CONCURRENT SESSION 02: SLE METRICS – IMPROVING OUTCOMES & MEASURES 22-05-2025 1:40 PM - 2:40 PM Background/Purpose The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)…
View article: Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force
Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force Open
Implementation of Treat-to-Target (T2T) in routine clinical practice remains low in systemic lupus erythematosus (SLE). Real-world data reveal excessive use of glucocorticoids (GCs) and frequently inadequate disease control. Here, an inter…
View article: Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway
Metabolic profiles of cutaneous lupus have abnormalities in the nicotinamide adenine dinucleotide pathway Open
Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role in cutaneous autoimmune diseases, such as cutaneous lupus erythematosus (CLE), is less well studied. An improved un…
View article: Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus
Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus Open
Background Patients with cutaneous lupus erythematosus (CLE) can present with one or multiple different subtypes of CLE. There is limited understanding of the prevalence and associated risk factors for having multiple CLE subtype diagnoses…
View article: Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus
Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus Open
Importance Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen …
View article: 307 The quest for biomarkers in cutaneous lupus erythematosus
307 The quest for biomarkers in cutaneous lupus erythematosus Open
Clinical challenges abound in cutaneous lupus erythematosus (CLE). Diagnosis of CLE is not straightforward because of its varied presentations and mimicry of other skin diseases. Up to half of CLE patients are recalcitrant to first-line t…
View article: 403 Trends in incidence and prevalence of atherosclerotic cardiovascular disease among patients with cutaneous lupus erythematosus from 2018–2020
403 Trends in incidence and prevalence of atherosclerotic cardiovascular disease among patients with cutaneous lupus erythematosus from 2018–2020 Open
Background Autoimmune disease such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), though whether similar increased ASCVD risk is…
View article: International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus
International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus Open
The 5th International Conference of Cutaneous Lupus Erythematosus was held in Tokyo, Japan on May 9 and 10, 2023. The latest topics on the pathogenesis, diagnosis, assessment, and treatment of cutaneous lupus erythematosus, dermatomyositis…
View article: P71 Treatment patterns, healthcare resource utilization and related costs of patients with discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) in the United States: a cohort study in the Merative™ MarketScan<sup>®</sup> database
P71 Treatment patterns, healthcare resource utilization and related costs of patients with discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) in the United States: a cohort study in the Merative™ MarketScan<sup>®</sup> database Open
Objective To describe treatment patterns and the economic burden of cutaneous lupus erythematosus (CLE) using data from a large, commercial insurance database in the United States. Existing data are relatively scarce and outdated. Methods …
View article: Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Open
Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
View article: Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Open
Supplementary Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
View article: Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Open
Purpose: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma (CTCL) characterized by neoplastic skin-homing T cells. To better understand the immunopathogenesis of MF, we analyzed the functional ability of peripheral blood mononuclear ce…
View article: Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Data from Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Open
Purpose: Mycosis fungoides (MF) is a cutaneous T-cell lymphoma (CTCL) characterized by neoplastic skin-homing T cells. To better understand the immunopathogenesis of MF, we analyzed the functional ability of peripheral blood mononuclear ce…